PCVX - Vaxcyte, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
San Carlos,
United States
Type: Equity
PCVX price evolution
PCVX
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $518.67 | $611.51 | $397.45 | $545.13 |
| Short term investments | $934.03 | $875.01 | $682.78 | $720.55 |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $1481.48 | $1517.07 | $1095.95 | $1295.43 |
| Long term investments | $400.35 | $414.35 | $163.78 | $169.67 |
| Property, plant & equipment | $152.75 | $113.74 | $110.62 | $27.76 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $605.79 | $574.23 | $311.96 | $200.62 |
| Total investments | $1334.37 | $1289.36 | $846.55 | $890.22 |
| Total assets | $2087.27 | $2091.3 | $1407.92 | $1496.06 |
| Current liabilities | ||||
| Accounts payable | $10.47 | $21.72 | $14.59 | $15.7 |
| Deferred revenue | ||||
| Short long term debt | $7.29 | $7.2 | $7.11 | $6.03 |
| Total current liabilities | $82.85 | $87.1 | $145.34 | $85.56 |
| Long term debt | $18.29 | $20.22 | $22.11 | $7.78 |
| Total noncurrent liabilities | $18.29 | $20.22 | $22.11 | $7.78 |
| Total debt | $25.58 | $27.42 | $29.22 | $13.81 |
| Total liabilities | $101.14 | $107.32 | $167.45 | $93.34 |
| Shareholders' equity | ||||
| Retained earnings | -$1148.12 | -$1019.41 | -$924.39 | -$743.59 |
| Other shareholder equity | $1.81 | $2.89 | $0.18 | -$2.29 |
| Total shareholder equity | $1986.13 | $1983.98 | $1240.47 | $1402.72 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $397.45 | $834.66 | $68.98 | $386.2 |
| Short term investments | $682.78 | $96.72 | $176.99 | |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $1095.95 | $942.55 | $256.35 | $389 |
| Long term investments | $163.78 | $27.42 | $27.99 | |
| Property, plant & equipment | $110.62 | $31.65 | $35.91 | $3.27 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $311.96 | $63.62 | $67.99 | $3.82 |
| Total investments | $846.55 | $124.14 | $204.97 | |
| Total assets | $1407.92 | $1006.18 | $324.34 | $392.83 |
| Current liabilities | ||||
| Accounts payable | $14.59 | $9.79 | $6.76 | $29.79 |
| Deferred revenue | ||||
| Short long term debt | $7.11 | $5.91 | $5.28 | |
| Total current liabilities | $145.34 | $40.52 | $28.72 | $46.86 |
| Long term debt | $22.11 | $12.03 | $11.51 | |
| Total noncurrent liabilities | $22.11 | $12.04 | $11.6 | $0.12 |
| Total debt | $29.22 | $17.94 | $16.78 | |
| Total liabilities | $167.45 | $52.56 | $40.32 | $46.98 |
| Shareholders' equity | ||||
| Retained earnings | -$924.39 | -$522.13 | -$298.64 | -$198.56 |
| Other shareholder equity | $0.18 | -$0.36 | -$0.24 | |
| Total shareholder equity | $1240.47 | $953.61 | $284.02 | $345.84 |
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $131.51 | $94.59 | $104.15 | $97.42 |
| Selling, general & administrative | $21.47 | $19.89 | $17.53 | $15.61 |
| Total operating expenses | $152.98 | $114.47 | $196.68 | $113.03 |
| Operating income | -$152.98 | -$114.47 | -$196.68 | -$113.03 |
| Income from continuing operations | ||||
| EBIT | -$128.7 | -$95.02 | -$180.8 | -$92.66 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$128.7 | -$95.02 | -$180.8 | -$92.66 |
| Income (for common shares) | -$128.7 | -$95.02 | -$180.8 | -$92.66 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $332.34 | $169.45 | $78.41 | $73.56 |
| Selling, general & administrative | $60.7 | $39.81 | $25.26 | $16.02 |
| Total operating expenses | $468.04 | $232.26 | $103.67 | $89.58 |
| Operating income | -$468.04 | -$232.26 | -$103.67 | -$89.58 |
| Income from continuing operations | ||||
| EBIT | -$402.27 | -$223.48 | -$100.07 | -$89.21 |
| Income tax expense | ||||
| Interest expense | $0 | $0.01 | $0.01 | |
| Net income | ||||
| Net income | -$402.27 | -$223.49 | -$100.08 | -$89.22 |
| Income (for common shares) | -$402.27 | -$223.49 | -$100.08 | -$89.22 |
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Net income | -$128.7 | -$95.02 | -$180.8 | -$92.66 |
| Operating activities | ||||
| Depreciation | $3.48 | $3.09 | $2.95 | $2.48 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $21.56 | $17.63 | $13.35 | $13.22 |
| Total cash flows from operations | -$121.39 | -$159.12 | -$128.81 | -$57.55 |
| Investing activities | ||||
| Capital expenditures | -$38.98 | -$12.07 | -$57.07 | -$7.34 |
| Investments | -$41.43 | -$439 | $43.14 | $29.62 |
| Total cash flows from investing | -$80.41 | -$451.07 | -$13.93 | $22.28 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $110.37 | $818.2 | $2.73 | $48.55 |
| Net borrowings | ||||
| Total cash flows from financing | $110.37 | $818.2 | $2.73 | $48.55 |
| Effect of exchange rate | -$1.41 | $6.06 | -$7.68 | $1.05 |
| Change in cash and equivalents | -$92.84 | $214.06 | -$147.68 | $14.33 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$402.27 | -$223.49 | -$100.08 | -$89.22 |
| Operating activities | ||||
| Depreciation | $10.17 | $9.2 | $3.46 | $1.41 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $48.76 | $23.65 | $10.73 | $5.43 |
| Total cash flows from operations | -$296.79 | -$170.6 | -$121.39 | -$46.63 |
| Investing activities | ||||
| Capital expenditures | -$67.88 | -$5.84 | -$6.53 | -$1.1 |
| Investments | -$705.43 | $80.43 | -$205.78 | |
| Total cash flows from investing | -$773.31 | $74.58 | -$212.31 | -$1.1 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $639.81 | $862.41 | $17.8 | $268.42 |
| Net borrowings | -$0.06 | |||
| Total cash flows from financing | $639.81 | $861.55 | $17.8 | $374.87 |
| Effect of exchange rate | -$6.69 | $0.14 | -$0.44 | $0.09 |
| Change in cash and equivalents | -$436.97 | $765.67 | -$316.34 | $327.22 |
News
Fundamentals
| Market cap | $12.95B |
|---|---|
| Enterprise value | $12.46B |
| Shares outstanding | 110.58M |
| Revenue | $0.00 |
|---|---|
| EBITDA | -$485.19M |
| EBIT | -$497.19M |
| Net Income | -$497.19M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -26.05 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | -25.68 |
| EV/EBIT | -25.06 |
| P/S ratio | N/A |
| P/B ratio | 6.53 |
| Book/Share | 17.95 |
| Cash/Share | 4.69 |
| EPS | -$4.50 |
|---|---|
| ROA | -28.08% |
| ROE | -30.07% |
| Debt/Equity | 0.13 |
|---|---|
| Net debt/EBITDA | 0.86 |
| Current ratio | 17.88 |
| Quick ratio | 17.88 |